InsidersTradesSigma
UNITED THERAPEUTICS Corp Stock: price and insider trades · United States · SEC (Form 4)
Track the UNITED THERAPEUTICS Corp stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, UNITED THERAPEUTICS Corp has published 1,230 public disclosures. Market capitalisation: €23.6bn. The latest transaction was filed on 8 July 2026 (Levée d'options). Among the most active insiders: EDGEMOND JAMES. All data is openly available.
In the past 90 days, UNITED THERAPEUTICS Corp reported a total of 354 insider trading declarations, with a total selling amount of approximately 133.84 million euros and no buying activity. The top insiders include Martine A Rothblatt, Chairperson & CEO, with sales totaling about 100.23 million euros across 173 declarations, James Edgemond, CFO and Treasurer, with approximately 66.89 million euros from 171 declarations, and Paul A Mahon, EVP & General Counsel, with around 5.09 million euros from 6 declarations. Notable recent sales include Edgemond's sale of approximately 1.95 million euros on April 24, 2026, and Rothblatt's sale of about 1.86 million euros on May 1, 2026. Other significant transactions by Rothblatt occurred on April 16 and April 24, 2026, with amounts ranging from approximately 1.81 million to 1.81 million euros.
Auto-generated summary, refreshed daily.Updated today
1,230
Insider Decl.
0
Thresholds
€341
1 ops.
Buy Volume
€272m
607 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate UNITED THERAPEUTICS Corp Buy (bullish), based on 13 analysts. Average price target: US$665.23.
35Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 2,273 of 25,804 companies
74.9
score / 100
Value58
Quality92
FCF yld4.4%
Earn yld5.7%
EV/EBITDA13.1x
ROE20%
Gross mgn88%
Net mgn42%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 8 July 2026
Declarations1,230 total
9,500 shares@ US$135.42Common StockSEC:0001106578-26-000093:0
200 shares@ US$553.1161Common StockSEC:0001106578-26-000093:1
241 shares@ US$554.3559Common StockSEC:0001106578-26-000093:2
596 shares@ US$555.5015Common StockSEC:0001106578-26-000093:3
726 shares@ US$556.554Common StockSEC:0001106578-26-000093:4
1,096 shares@ US$557.777Common StockSEC:0001106578-26-000093:5
1,875 shares@ US$558.9003Common StockSEC:0001106578-26-000093:6
3,399 shares@ US$559.7613Common StockSEC:0001106578-26-000093:7
505 shares@ US$560.4907Common StockSEC:0001106578-26-000093:8
800 shares@ US$562.596Common StockSEC:0001106578-26-000093:9
62 shares@ US$563.2381Common StockSEC:0001106578-26-000093:10
9,500 shares@ US$135.420.0054% mcap0.8% of flowCommon StockSEC:0001106578-26-000092:0
2,098 shares@ US$546.93410.0048% mcap0.7% of flowCommon StockSEC:0001106578-26-000092:1
1,031 shares@ US$548.000.0024% mcap0.4% of flowCommon StockSEC:0001106578-26-000092:2
3,354 shares@ US$549.03360.0078% mcap1.1% of flowCommon StockSEC:0001106578-26-000092:3
2,116 shares@ US$549.86520.0049% mcap0.7% of flowCommon StockSEC:0001106578-26-000092:4
329 shares@ US$550.77550.0008% mcap0.1% of flowCommon StockSEC:0001106578-26-000092:5
131 shares@ US$551.88460.0003% mcap0.0% of flowCommon StockSEC:0001106578-26-000092:6
135 shares@ US$553.38780.0003% mcap0.0% of flowCommon StockSEC:0001106578-26-000092:7
306 shares@ US$553.90460.0007% mcap0.1% of flowCommon StockSEC:0001106578-26-000092:8
8,750 sharesCommon StockSEC:0001636178-26-000029:0
164 sharesCommon StockSEC:0001636178-26-000029:1
865 sharesCommon StockSEC:0001636178-26-000029:2
1,091 sharesCommon StockSEC:0001636178-26-000029:3
840 sharesCommon StockSEC:0001636178-26-000029:4
25 of 1230 declarations
About UNITED THERAPEUTICS Corp
United Therapeutics Corp. (ticker: UTHR) is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States, with its principal headquarters in Silver Spring, Maryland. Founded in 1996, the company has built a focused franchise around pulmonary vascular disease and select rare diseases, giving it a specialized market position with relatively defensive characteristics and a revenue base concentrated in a handful of recognizable brands. The core business is centered on therapies for pulmonary arterial hypertension (PAH) and, more recently, pulmonary hypertension associated with interstitial lung disease (PH-ILD). Key commercial products include Tyvaso and Tyvaso DPI, Remodulin, Orenitram, and Adcirca. United Therapeutics also markets Unituxin, an FDA-approved antibody therapy for high-risk neuroblastoma, a rare pediatric cancer. This product mix makes the company stand out: it combines orphan-disease exposure with high-value specialty pharmaceuticals, while remaining highly dependent on execution in commercialization, reimbursement access, and intellectual-property protection. From a historical perspective, United Therapeutics was founded in 1996 and has evolved from a niche therapeutics company into a broader biopharmaceutical group. The company emphasizes research, clinical development, and pipeline expansion, which are intended to extend the life cycle of existing franchises and create future growth drivers. Its geographic footprint remains predominantly U.S.-based, with a major operational presence in Silver Spring and an additional hub in Research Triangle Park, North Carolina. Competitively, United Therapeutics has established a strong position in PAH through brand recognition, clinical expertise, and long-standing relationships with specialist prescribers. Management highlights its capabilities in inhaled and prostacyclin-based therapies, where differentiation depends not only on efficacy but also on ease of administration and patient support. The portfolio is concentrated, but it supports meaningful cash flow visibility and a durable specialty-pharma profile. Recent highlights include the company’s report in July 2025 of record quarterly financial results, driven by double-digit growth in products such as Tyvaso DPI, nebulized Tyvaso, Orenitram, and Unituxin. Investors should nevertheless monitor pipeline milestones, potential competition across key franchises, and evolving regulatory dynamics. Overall, UTHR remains a high-quality healthcare/pharma name with a niche growth profile, listed on the NASDAQ in the United States and anchored by specialty respiratory and rare-disease franchises.
